Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.49 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | JAK1 | P23458 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 2/20 | 0.47 |
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.44 |
| ▸ | USP7 | Q93009 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4005405 | 0.90 | RORC (0.54) | TACR1JAK2JAK1STSRORC | |
| SCHEMBL6694621 | 0.90 | SCN9A (0.49) | TACR1RORCGPR119SCN9APDE4B | |
| SCHEMBL5459736 | 0.90 | SCN9A (0.49) | TACR1RORCGPR119SCN9APDE4B | |
| SCHEMBL18345004 | 0.90 | SCN9A (0.49) | TACR1RORCGPR119SCN9APDE4B | |
| SCHEMBL4436548 | 0.90 | SCN9A (0.49) | TACR1RORCGPR119SCN9APDE4B | |
| SCHEMBL4760197 | 0.90 | SCN9A (0.49) | TACR1RORCGPR119SCN9APDE4B | |
| SCHEMBL29450269 | 0.89 | STS (0.49) | STSGPR119SCN9APDE4B | |
| SCHEMBL18618417 | 0.89 | STS (0.49) | STSGPR119SCN9APDE4B | |
| SCHEMBL18618432 | 0.89 | STS (0.49) | STSGPR119SCN9APDE4B | |
| SCHEMBL18619384 | 0.87 | PDE4B (0.47) | TACR1JAK2STSGPR119SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1966137-A2 | PIPERIDINE DERIVATIVES | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072150-A2 | PIPERIDINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | PFIZER INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142389-A1 | PIPERIDINE DERIVATIVES | CFTR, HDAC10, RPP30 | TACR1 98/4885JAK2 21/4885JAK1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.